ClinicalTrials.gg
RecruitingNCT07235293Updated Aug 20, 2026

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

A Phase 2 interventional study of DSP107 + Atezolizumab and Fruquintinib in Colorectal Cancer, sponsored by Kahr Bio Australia Pty Ltd. Recruiting at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Kahr Bio Australia Pty Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing atezolizumab in Colorectal Neoplasms — 4 open to participants now, 8 under way, 3 of them phase 3. atezolizumab · Colorectal Neoplasms.

Planned enrollment
10th of 19
90 · median 80
Started
2026
the only one that year
Phase 2
11 of 19
2 open now
Registered
20th of 19
by date

Among the 19 studies testing atezolizumab in Colorectal Neoplasms, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 11 in phase 2, and was the 20th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 19 studies testing atezolizumab in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing atezolizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Read the detailed description

This Phase 2b, randomized, open-label, multicenter study will enroll participants with advanced MSS or mismatch repair-proficient (pMMR) colorectal cancer who have progressed on, or shown intolerance to, standard therapies, including fluoropyrimidine, irinotecan, oxaliplatin, trifluridine/tipiracil (Lonsurf), bevacizumab, and epidermal growth factor receptor (EGFR) inhibitors if RAS wild-type. Participants with BRAF V600E mutation, HER2 amplification/overexpression, KRAS G12C mutation, RET fusion, or NTRK fusion may also have received one prior targeted therapy. Prior treatment with fruquintinib or regorafenib is not allowed.

Participants will be randomized 1:1 into two arms:

Group A (Experimental): DSP107 10 mg/kg intravenously on Days 1, 8, and 15 of each 28-day cycle, administered after atezolizumab 1680 mg IV on Day 1 of each cycle. DSP107 infusion may be shortened after initial tolerance. Atezolizumab infusion may be shortened from 60 to 30 minutes if well tolerated.

Group B (Active Comparator): Fruquintinib 5 mg orally once daily on Days 1-21 of each 28-day cycle, with dosing diaries maintained by participants.

Total duration of study participation for each participant will vary based on factors including treatment tolerability, disease progression and other study discontinuation criteria.

Study duration for participants will include at least:

  • Screening Period of up to 28 days
  • Treatment Period of up to 24 cycles of 28 days
  • Safety Follow-up Period of up to 90 days* from the last dose of IP or active comparator.
  • LTFU for a period of up to 5 years from randomization.
03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are ≥ 18 years of age with a of > 3 months.
  2. Participants with confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 ).
  3. per v1.1.

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) unless stable 2 months post definitive therapy with .
  2. Unresolved AEs of Grade 2 or higher from prior anticancer therapy.
  3. Past or current history of disease or immune deficiency.
  4. History of other within 3 years of first study treatment cycle.
  5. Current or recent treatment with certain therapies including specified anticancer treatments, modulators of and immunomodulating therapies (prior treatment with CPIs is not exclusory).
  6. Known allergy or to any of the test compounds, materials, or to test product.
  7. abnormal laboratory safety tests.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    DSP107 in combination with Atezolizumab

    DSP107 10 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle. Atezolizumab 1680 mg IV on Day 1 of each 28-day cycle.

    Drug: DSP107 + Atezolizumab

  • Active comparator
    Fruquintinib

    Participants will receive fruquintinib orally in 28-day cycles, for up to 24 cycles (96 weeks), or until disease progression, unacceptable toxicity, or study withdrawal.

    Drug: Fruquintinib

Interventions

  • DrugDSP107 + Atezolizumab

    Drug pages: SIRPa-4-1BBL Fusion Protein DSP107 · Atezolizumab

    DSP107 infusion begins \~30 (±10) minutes after completion of atezolizumab infusion on Day 1.

  • 5 mg orally, once daily (with or without food), on Days 1-21 of each 28-day cycle, followed by 7 days off.

06

What researchers measure

Primary outcomes

  1. To determine Median overall survival (mOS) in participants treated with the combination of DSP107 and atezolizumab versus fruquintinib.

    Median Overall Survival (mOS) will be estimated using Kaplan-Meier methodology as the median time from the start of study treatment to the last known date a participant was alive. Censoring rules will be applied for participants without an event at the time of analysis, and 95% confidence intervals for mOS will be provided.

    Time frame: From Day 1 until date of death from any cause assessed up to 2 years

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    Safety and tolerability of DSP107 + atezolizumab versus fruquintinib, assessed by incidence and severity of AEs per CTCAE v5.0 (including SAEs and AESIs).

    Time frame: From Screening to Follow-up (30 to 90 Days Post IP)

  2. Changes in 12-lead ECG parameters

    Safety assessment based on changes from baseline in ECG intervals (PR, QRS, QT, QTc) and heart rate.

    Time frame: From Baseline through to end of treatment visit, an average of 6 months

  3. Change in Overall Survival (OS)

    All randomized participants will continue to the LTFU phase of the study to allow determination of overall survival

    Time frame: From randomization through study participation, with survival follow up at approximately 4-month (± 1 month) intervals for up to 5 years from randomization

  4. Change from Baseline in Quality of Life (QoL)

    Evaluation of the effect of treatment on quality of life (QoL) using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).

    Time frame: From Baseline through to end of treatment visit, an average of 6 months

  5. Change from Baseline in Systolic and Diastolic Blood Pressure

    Mean change from baseline in blood pressure (mmHg).

    Time frame: From Baseline through to end of treatment visit, an average of 6 months

  6. Change from Baseline in Pulse Rate

    Mean change from baseline in heart rate (beats per minute).

    Time frame: From Baseline through to end of treatment visit, an average of 6 months

  7. To evaluate the immunogenicity of DSP107 when administered in combination with atezolizumab.

    Immunogenicity will be assessed by measurement of anti-drug antibodies (ADAs) to DSP107 in serum samples collected at specified time points.

    Time frame: From Baseline through to end of treatment visit, an average of 6 months

07

Study locations

18 of 18 sites recruiting
  • University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP)
    Aurora, Colorado 80045, United States
    Recruiting
    • Hannah Robinson · Principal investigator
  • University of Colorado Cancer Center - Highlands Ranch Hospital
    Highlands Ranch, Colorado 80129, United States
    Recruiting
    • Hannah Robinson · Principal investigator
  • Mayo Clinic
    Florida City, Florida 32224, United States
    Recruiting
    • Conor O'Donnell, Dr · Principal investigator
  • Duke University Medical Center - Duke Cancer Center
    Durham, North Carolina 27710, United States
    Recruiting
    • Nicholas DeVito · Principal investigator
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Anwaar Saeed, MD · Principal investigator
  • The University of Texas MD Anderson Cancer Center
    Texas City, Texas 77030, United States
    Recruiting
    • Maria Pia Morelli, MD · Principal investigator
  • The Queen Elizabeth Hospital
    Woodville, Adelaide 5011, Australia
    Recruiting
    • Timothy Jay Price, Dr · Principal investigator
  • Chris O'brien Lifehouse
    Camperdown, New South Wales 2050, Australia
    Recruiting
    • Sarah Isabella MacKenzie Sutherland, Dr · Principal investigator
  • Port Macquarie Base Hospital (Mid North Coast Cancer Institute), Wrights Road,
    Port Macquarie, New South Wales 2444, Australia
    Recruiting
    • Dr Stephen Donald Begbie · Principal investigator
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Adnan Mahmood Nagrial, Associate Professor · Principal investigator
  • Icon Cancer Centre
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • Jermaine lan George Coward, A/Prof · Principal investigator
  • Flinders Medical Centre SA
    Bedford Park, South Australia 5042, Australia
    Recruiting
    • Christos Stelios Karapetis, Prof · Principal investigator
  • Monash Health
    Clayton, Victoria 3168, Australia
    Recruiting
    • David Kar Wah Lau, Dr · Principal investigator
  • Footscray Hospital - Western Health
    Footscray, Victoria 3011, Australia
    Recruiting
    • Peter Gibbs, Prof · Principal investigator
  • Austin Health
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • Niall Christopher Tebbutt, Prof · Principal investigator
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
    • Andrew Mark Meurisse Haydon, Dr · Principal investigator
  • Sunshine Hospital - Western Health
    Saint Albans, Victoria 3021, Australia
    Recruiting
    • Peter Gibbs, Prof · Principal investigator
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Rajiv Narayan Shinde, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2026, 8 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 8 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 19, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07235293
Lead sponsor
Kahr Bio Australia Pty Ltd
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Jan 16, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Adam Foley Comer
Contact
adam@kahrbio.com
+972 54 749 1753

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SIRPa-4-1BBL Fusion Protein DSP107 · Atezolizumab

Start the discussion